Two Sigma Advisers LP Takes Position in Fresenius Medical Care AG & Co. (FMS)

Share on StockTwits

Two Sigma Advisers LP acquired a new stake in Fresenius Medical Care AG & Co. (NYSE:FMS) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 21,000 shares of the company’s stock, valued at approximately $680,000.

Several other large investors also recently added to or reduced their stakes in FMS. Two Sigma Investments LP purchased a new stake in Fresenius Medical Care AG & Co. during the fourth quarter valued at about $7,553,000. Barclays PLC lifted its holdings in Fresenius Medical Care AG & Co. by 399.9% during the fourth quarter. Barclays PLC now owns 15,518 shares of the company’s stock valued at $503,000 after purchasing an additional 12,414 shares during the last quarter. Sustainable Insight Capital Management LLC lifted its holdings in Fresenius Medical Care AG & Co. by 145.7% during the fourth quarter. Sustainable Insight Capital Management LLC now owns 11,619 shares of the company’s stock valued at $752,000 after purchasing an additional 6,891 shares during the last quarter. QS Investors LLC purchased a new stake in Fresenius Medical Care AG & Co. during the fourth quarter valued at about $58,000. Finally, Geode Capital Management LLC lifted its holdings in Fresenius Medical Care AG & Co. by 13.0% during the fourth quarter. Geode Capital Management LLC now owns 11,854 shares of the company’s stock valued at $383,000 after purchasing an additional 1,367 shares during the last quarter. Institutional investors own 1.88% of the company’s stock.

Several research firms have commented on FMS. DZ Bank reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a report on Tuesday, March 5th. SunTrust Banks upped their price target on Fresenius Medical Care AG & Co. to $48.00 and gave the company a “positive” rating in a research report on Thursday, February 21st. Zacks Investment Research upgraded Fresenius Medical Care AG & Co. from a “sell” rating to a “hold” rating in a research report on Tuesday, February 19th. Finally, Royal Bank of Canada reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, March 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $65.00.

Shares of FMS opened at $40.07 on Thursday. Fresenius Medical Care AG & Co. has a twelve month low of $30.99 and a twelve month high of $53.40. The stock has a market cap of $25.47 billion, a PE ratio of 17.65, a P/E/G ratio of 2.37 and a beta of 1.40. The company has a current ratio of 1.25, a quick ratio of 1.02 and a debt-to-equity ratio of 0.39.

Fresenius Medical Care AG & Co. (NYSE:FMS) last announced its quarterly earnings results on Wednesday, February 20th. The company reported $0.66 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.64 by $0.02. Fresenius Medical Care AG & Co. had a return on equity of 10.14% and a net margin of 12.00%. The firm had revenue of $4.91 billion for the quarter, compared to analysts’ expectations of $5.01 billion. As a group, sell-side analysts predict that Fresenius Medical Care AG & Co. will post 2.47 earnings per share for the current fiscal year.

WARNING: “Two Sigma Advisers LP Takes Position in Fresenius Medical Care AG & Co. (FMS)” was originally published by Macon Daily and is the property of of Macon Daily. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://macondaily.com/2019/04/18/two-sigma-advisers-lp-takes-position-in-fresenius-medical-care-ag-co-fms.html.

About Fresenius Medical Care AG & Co.

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Featured Story: Retained Earnings

Institutional Ownership by Quarter for Fresenius Medical Care AG & Co. (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.